NRG-BR002 trial finds ablation does not improve survival in oligometastatic breast cancer
A randomized clinical trial found that adding metastasis-directed ablation (focused radiation or surgery) to first-line systemic therapy did not improve progression-free or overall survival in patients with oligometastatic breast cancer. Two-year overall survival was 88.4% with systemic therapy alone versus 78% with ablation added.
2 sourcesClinical trials
00